stockrow
Friday 6 November 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
Standard BioTools Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.3 million, down 6.24% from fiscal 2024.
- Revenue
- −0.85%
- EPS
- +138.1%
- Free cash flow
- +73.3%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
0.63
0.01
+1.61%
Follow LAB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 4.60 | 3.73 | 2.15 |
P/S ratio |
5.72 | 4.14 | 3.79 | 3.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(410.49) | (7.66) | (31.09) | (47.27) | |
P/B ratio |
1.15 | 0.64 | 0.59 | 0.52 | |
Price to Tangible BV |
1.72 | 0.85 | 0.80 | 0.70 | |
EV/Sales |
3.59 | (1.08) | (1.78) | (1.95) | |
EV/EBITDA |
0.00 | 1.03 | 1.62 | 2.04 | |
EV/Operating CF |
(4.12) | 1.02 | 1.88 | 2.56 | |
EV/FCF |
(3.43) | 0.92 | 1.69 | 2.28 | |
Quick Ratio |
1.86 | 11.77 | 8.67 | 9.29 | |
Current Ratio |
4.19 | 12.36 | 9.10 | 9.75 | |
Net Debt/EBITDA |
7.86 | 38.81 | 18.81 | 23.31 | |
Debt/Assets |
0.05% | 0.05% | 0.05% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.14 | 0.14 | 0.14 | 0.14 | |
Operating CF/Net income |
(0.06) | (0.37) | 0.39 | (0.46) | |
Capex/Depreciation |
(0.57) | (0.73) | (5.21) | 0.00 | |
Interest Coverage |
(1,540.25) | — | — | — | |
Research and Development Expense of Revenue |
33.49% | 10.01% | 9.83% | 10.72% | |
Selling, General and Administrative Expense of Revenue |
106.48% | 87.99% | 81.52% | 86.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
24.14% | 41.73% | 20.15% | 19.21% | |
Graham Net Nets |
0.64 | 1.24 | 1.34 | 1.43 | |
Graham Number |
0.00 | 2.55 | 2.62 | 3.31 | |
Earnings Yield |
(15.63%) | 21.74% | 26.83% | 46.53% | |
Free Cash Flow Yield |
(18.27%) | (28.30%) | (27.82%) | (24.81%) | |
Revenue per Share |
0.06 | 0.05 | 0.05 | 0.05 | |
Operating CF per Share |
0.00 | (0.12) | (0.03) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.12) | (0.03) | (0.02) | |
Cash per Share |
0.49 | 1.17 | 1.22 | 1.17 | |
Shareholders Equity per Share |
1.11 | 1.45 | 1.38 | 1.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.11 | 1.45 | 1.38 | 1.41 | |
Free Cash Flow |
(1.67) | (47.17) | (10.65) | (6.16) | |
Working Capital |
345.96 | 479.25 | 460.07 | 446.28 | |
Capital Expenditures |
(0.48) | (0.57) | (0.34) | 0.00 | |
Net Current Asset Value |
310.80 | 443.46 | 429.62 | 417.72 | |
EV/EBIT |
0.00 | 0.97 | 1.58 | 2.00 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.09 | 38.56 | 15.18 | 13.26 | |
Average Payables |
5.23 | 9.89 | 8.44 | 5.04 | |
Average Inventory |
20.36 | 30.36 | 20.64 | 21.52 | |
Average Assets |
590.05 | 609.36 | 592.09 | 587.48 | |
Average Common Equity |
448.01 | 507.86 | 482.25 | 477.70 |
Columns are period end dates · fundamentals updated 5 Nov 2026